The Rapid Pace of Vaccine Innovation Challenges the Conventional Model of Biopharma Delivery Methods
Needle-free injectors also known as “jet injectors” have evolved over the last decade.
Initially designed to alleviate needlestick injuries, needle reuse and cross-contamination, needle-free was then embraced by WHO to address polio vaccine supply shortages.
Today, PharmaJet’s market-leading needle-free innovations are still alleviating needlestick injuries, needle reuse, cross-contamination, and supply shortages while return customers are reporting cost savings, improved injectable performance, and the high level of user satisfaction. Below, you can access the publications that demonstrate how needle-free makes injections better.
How Does Needle-free Work?
PharmaJet’s Needle-free Injection Systems deliver a spring-powered injection in 1/10 of a second by means of a narrow stream of fluid that penetrates the skin with a precise dose and depth. There is no need for an external power source and there is no needle.
Our two commercialized systems are the Tropis® Intradermal System and the Stratis® Intramuscular or Subcutaneous System. Each system delivers a fixed dose of 0.1 ml and 0.5 ml respectively. Both systems are validated and commercially available with regulatory clearances. Both provide an alternative to traditional needle and syringe or electroporation delivery with superior clinical results. And both can provide an improved patient and caregiver experience with increased safety and comfort which also has resulted in increased vaccine compliance – very relevant today as we hear more and more about vaccine hesitancy in the news.
PharmaJet Needle-free Injection
Spring-powered injectors deliver vaccine or therapeutic by means of a narrow stream of fluid that penetrates the skin in about 1/10 of a second.
✓ No External Power Source ✓ No Needle
PharmaJet Tropis®
0.1 ml Intradermal
Injection
Benefits
Improved Clinical Results
- Alternative to needle or electroporation
- Higher efficacy compared to N/S
- Comparable to electroporation
Validated Commercial Devices
- 0.1 ml ID routes or 0.5 ml IM/SC
- Dose savings potential
Improved Patient and Caregiver Experience
- Increased vaccine compliance
- Safety and Comfort
PharmaJet Stratis®
0.5 ml Intramuscular/Subcutaneous Injection
Reduce Healthcare Costs
- Reduced dose volume, enabled by Tropis ID delivery, can decrease vaccine delivery costs by 50%
- Needle-free eliminates sharps management and disposal costs
- Healthcare worker safety is increased while needlestick injury testing and treatment costs disappear